Genmab (GMAB)
(Real Time Quote from BATS)
$25.55 USD
-0.93 (-3.51%)
Updated Sep 20, 2024 03:54 PM ET
After-Market: $25.53 -0.02 (-0.08%) 4:16 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 1 - 20 ( 121 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Recieves EU Approval in R/R FL; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Genmab Assumes Full Rights for Acasunlimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX FASPRO Approved for Newly-Diagnosed MM Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q24 DARZALEX Sales Beat Our Forecast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
EPKINLY Receives FDA Approval in R/R FL; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
European Hematology Association 2024 Congress Key Takeaways; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Key ASCO Takeaways; Epcoritamab and Acasunlimab Shine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Eight Clinical Datasets Expected for Epcoritamab at EHA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q24 Financials; EPKINLY FDA Decision in r/r FL in June; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TIVDAK Receives Full FDA Approval in r/r Cervical Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ProfoundBio Deal Adds ADCs to Genmab''s Armory; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX NICE-Endorsed in Newly-Diagnosed AL Amyloidosis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
EPKINLY Supplemental Biologics License Application in r/r FL; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2023 Financials Reported; Numerous Catalysts Expected in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 2023 Sales Reported; Genmab Appeal Denied; Modulating PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous Datasets Presented at ASH Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Positive Follicular Lymphoma Regulatory Feedback; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for GMAB 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
sBLA Submitted For RYBREVANT + Chemo in EGFR+ NSCLC Post-Tagrisso; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R